The revenue in the pharmaceuticals market in France was forecast to continuously increase between 2024 and 2029 by in total *** billion U.S. dollars (+***** percent). After the sixth consecutive increasing year, the indicator is estimated to reach **** billion U.S. dollars and therefore a new peak in 2029. Find further information concerning the revenue in the pharmaceuticals market in Bolivia and the revenue in the pharmaceuticals market in Ecuador. The Statista Market Insights cover a broad range of additional markets.

In 2023, the leading company within the French pharmaceutical industry was Sanofi Winthrop Industrie, a subsidiary of the Sanofi Group, with a French-based revenue of over nearly ** billion euros.

Recent developments include: In January 2024, France-based SANOFI agreed to acquire a U.S.-based drug development project of INBRX-101 from the parent company Inhibrx Inc. for around 2.2 billion dollars to escalate the business of rare diseases. This acquisition will help to enhance the company’s revenues from the anti-inflammatory drugs and boost the R&D domain of the company. , In November 2023, AbbVie announced the agreement with ImmunoGen and its significant cancer therapy namely ELAHERE. This acquisition will accelerate AbbVie’s commercial and clinical expansion in the tumor section. In addition, ELAHERE is the first-in-class antibody-drug conjugate (ADC) which will help to supplement the ADCs division of AbbVie. , In 2022, Sanofi and AstraZeneca together developed the world’s first vaccine against bronchiolitis. AstraZeneca spent 585 euro million for manufacturing the product while Sanofi handled the marketing of the product. .

Forecast: Total Pharmaceutical Market in France 2024 - 2028 Discover more data with ReportLinker!

The generic pharmaceuticals market in France represented a share of **** percent of the French pharmaceutical market in 2015. Nine years prior to that, the share of these pharmaceuticals products in the pharmaceutical market in France was barely * percent.

The France Active Pharmaceutical Ingredients (API) Market is Segmented by Business Mode (Captive API and Merchant API), Synthesis Type (Synthetic and Biotech), Drug Type (Generic and Branded), and Application (Cardiology, Oncology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Other Applications). The report offers the value (in USD billion) for the above segments.

The French Active Pharmaceutical Ingredients (API) market, valued at approximately €1.5 billion in 2025, is projected to experience robust growth, driven by a compound annual growth rate (CAGR) of 6.10% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of chronic diseases like cardiovascular conditions and cancer necessitates a higher demand for pharmaceuticals, consequently boosting the API market. Furthermore, growing R&D investments by pharmaceutical companies in France are leading to the development of innovative drugs and formulations, increasing the need for advanced APIs. The rise in outsourcing of API manufacturing to specialized companies due to cost efficiency and technological expertise is also contributing to market expansion. Specific growth within segments is expected to be driven by a preference towards branded drugs over generics in certain therapeutic areas, and significant demand for APIs used in oncology and cardiology treatments. The captive API segment will likely see considerable growth due to increased vertical integration by major pharmaceutical players. However, the market's growth is not without its challenges. Stringent regulatory requirements for API manufacturing and approval processes can create delays and increase production costs. Supply chain disruptions, particularly concerning raw materials and specialized chemicals, pose a significant risk. Fluctuations in currency exchange rates and global economic instability also pose headwinds to the consistent expansion of the market. Despite these constraints, the projected growth trajectory is overwhelmingly positive, indicating a strong outlook for the French API market over the next decade. The market's segmentation by business mode (captive vs. merchant), synthesis type (synthetic vs. biotech), drug type (generic vs. branded), and application area allows for a granular understanding of market dynamics and helps identify areas of greatest potential for investment and growth. Recent developments include: October 2022: MilliporeSigma opened a 700-square-meter (29,000-square-foot) commercial facility for its new Millipore CTDMO Services in France to produce monoclonal antibodies and other recombinant proteins. The CTDMO service spans pre-clinical to commercial phases, including testing, across multiple modalities, including mAbs, highly potent active pharmaceutical ingredients, antibody-drug conjugates, viral vector therapies, mRNA, and lipid nanoparticle formulation., July 2022: As part of a wider project funded by the 'France Relance' Plan, the Novasep-PharmaZell Group committed EUR 7.3 million in its Mourenx facility (southwestern France) to build a multipurpose pilot workshop inside one of its production units. The new industrial instrument will support the development of the Mourenx site and the ongoing need to produce active pharmaceutical ingredients (APIs), particularly the highly potent medicines (HPAPIs) used to treat cancer.. Key drivers for this market are: Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders, Increasing Adoption of Biologicals and Biosimilars; Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drugs Research. Potential restraints include: Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders, Increasing Adoption of Biologicals and Biosimilars; Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drugs Research. Notable trends are: Oncology Segment Expects to Register a Healthy CAGR.

Forecast: Pharmaceutical Industry Export Market Share in France 2023 - 2027 Discover more data with ReportLinker!

The France drug delivery devices market is poised for steady growth, projected to reach a significant value over the forecast period (2025-2033). Driven by factors such as an aging population necessitating increased medication adherence, advancements in drug delivery technologies (like personalized and targeted therapies), and a rise in chronic diseases like cancer and cardiovascular conditions, the market demonstrates substantial potential. The injectable route of administration currently holds the largest segment share, fueled by the prevalence of injectable medications for various therapeutic areas. However, other routes like topical and inhaled drug delivery systems are experiencing notable growth due to improved patient convenience and reduced side effects. Hospitals and ambulatory centers remain the dominant end-users, but the market is seeing expansion in other end-users as well. The competitive landscape is characterized by both established pharmaceutical giants and emerging specialized companies, leading to increased innovation and market diversification. This competitive pressure fosters continuous improvement in drug delivery system design, efficacy, and affordability. Growth is projected to be moderately paced, reflecting the mature nature of the pharmaceutical market in France alongside the regulatory complexities involved in introducing new drug delivery devices. Despite this, the market remains attractive due to consistent demand for advanced drug delivery solutions. Key market restraints include stringent regulatory approvals, high R&D costs associated with innovative delivery mechanisms, and price sensitivity among payers. Nonetheless, the overall market outlook remains positive, with opportunities for growth driven by the aforementioned market drivers and the potential for partnerships between pharmaceutical companies and device manufacturers to bring innovative solutions to market. The market segmentation by application (cancer, cardiovascular, diabetes, infectious diseases) provides insights into the specific therapeutic areas driving demand within this sector. Recent developments include: September 2022: Biocorp, a French company specializing in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of the SoloSmart Injection Pen., July 2022: EVEON announced the launch of the INDENEO European consortium project for the Uncommon Disease Research (RDR) Challenge Call to develop a delivery system from the nose to the brain to treat rare central nervous system (CNS) illnesses such as encephalitis in neonates.. Key drivers for this market are: Increased Prevalence of Chronic Diseases, Technological Advances. Potential restraints include: Increased Prevalence of Chronic Diseases, Technological Advances. Notable trends are: Diabetes Segment is Estimated to Witness Healthy Growth over the Forecast Period.

Pharmaceuticals in Dosage Market Size Value in France, 2021 Discover more data with ReportLinker!

Significant fluctuations are estimated for all segments over the forecast period for the revenue. In general, the indicator appears to exhibit a positive trend, with more segments showing increasing values rather than decreasing values until 2029. Among them, the segment Oncology Drugs attains the highest value throughout the entire period, reaching *** billion U.S. dollars. Find further statistics on other topics such as a comparison of the revenue in Italy and a comparison of countries or regions regarding the revenue. The Statista Market Insights cover a broad range of additional markets.

Pharmaceuticals in Dosage Market Size Value Per Capita in France, 2023 Discover more data with ReportLinker!

Forecast: Pharmaceuticals in Dosage Market Size Value in France 2024 - 2028 Discover more data with ReportLinker!

France Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides), and Geography. The report offers the value (in USD million) and volume (in Units million) for the above segments.

Snapshot img

Bio-Pharma Market Size 2025-2029

The bio-pharma market size is forecast to increase by USD 311.8 billion at a CAGR of 9% between 2024 and 2029.

The market is witnessing significant growth, driven by the increasing prevalence of health disorders and the rise in the production of vaccines. Biopharmaceuticals address a broad spectrum of diseases, such as cancer, diabetes, psoriasis, rheumatoid arthritis, genetic mutations, and various other conditions. The global health landscape is shifting, with an increasing focus on preventive healthcare and the development of innovative treatments. This trend is particularly pronounced in the Bio-Pharma sector, where the production of vaccines and specialized therapies is at an all-time high. However, the market also faces challenges, including the high cost of bio-pharmaceuticals. This cost burden can limit access to essential treatments for many patients, particularly in developing countries.
To succeed, they must focus on cost reduction strategies, such as process optimization and supply chain efficiencies, while also investing in research and development to bring innovative, cost-effective treatments to market. By addressing these challenges and leveraging the market's growth drivers, Bio-Pharma companies can position themselves for long-term success. The global population is aging, leading to an increase in chronic diseases such as cancer, type 2 diabetes, and cardiovascular diseases. Companies operating in this space must navigate these challenges while capitalizing on the market's opportunities.

What will be the Size of the Bio-Pharma Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market is experiencing significant trends and potential for growth, driven by the value proposition they offer in terms of cost savings and increased patient access to biologic therapies. The biosimilar market landscape is shaped by various factors, including patent expirations, regulatory approvals, and competition. Biosimilar analytical methods play a crucial role in demonstrating similarity between the reference biologic and the biosimilar, ensuring comparable bioavailability, pharmacodynamics, and pharmacokinetics. Clinical trials are essential to prove biosimilar efficacy, safety, and interchangeability, while regulatory agencies assess the quality attributes and manufacturing capabilities of biosimilars. The biosimilar patent landscape is complex, with numerous patents expiring and new ones being granted, impacting market share and competition.
The pricing of biosimilars is a critical consideration, with potential for significant cost savings for healthcare systems and patients. Biosimilar substitution and interchangeability are key aspects of market adoption, with regulatory approvals enabling automatic substitution in some cases. Safety and immunogenicity are essential considerations, as biosimilars may have unique risks compared to their reference biologics. Despite these challenges, the biosimilar market offers significant investment opportunities, as the demand for affordable biologic therapies continues to grow. The regulatory landscape is evolving, with a focus on streamlining approval processes and increasing transparency. Litigation is an ongoing concern, with patent disputes and regulatory challenges impacting market dynamics. The key driver for the market is the production of vaccines, which has gained significant momentum in recent years due to the ongoing COVID-19 pandemic.

How is this Bio-Pharma Industry segmented?

The bio-pharma industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Monoclonal antibodies
  Recombinant growth factors
  Vaccines
  Recombinant hormones
  Others


Application

  Oncology
  Autoimmune disorder
  Metabolic disorder
  Hormonal disorder
  Others


Drug Class

  Proprietary biologics
  Biosimilars


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period. Monoclonal antibodies, a segment of high-priced yet life-saving biologic drugs, hold a significant share in the market. Despite having lower sales volumes compared to other pharmaceutical products, the revenues generated from monoclonal antibodies are substantial due to their high price point. This market segment is poised for growth during the forecast period, with numerous companies inve

Forecast: Pharmaceutical Industry Exports in France 2023 - 2027 Discover more data with ReportLinker!

Forecast: Pharmaceutical Goods Market Size Value in France 2024 - 2028 Discover more data with ReportLinker!

France Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Diabetes, Oncology, Cardiovascular Diseases and More), End User (Hospitals, Ambulatory Surgical & Specialty Clinics and More). The Market and Forecasts are Provided in Terms of Value (USD).

France Active Pharmaceutical Ingredients (API) Market size was valued at USD 1.13 Billion in 2024 and is projected to reach USD 1.68 Billion by 2032, growing at a CAGR of 5.08% from 2026 to 2032.

France Active Pharmaceutical Ingredients (API) Market Drivers

Growing Geriatric Population and Chronic Diseases: France has a rising elderly population and an increasing incidence of chronic diseases such as cardiovascular diseases, cancer, and diabetes. This drives the demand for pharmaceutical drugs and, consequently, APIs. Increasing Demand for Generic Drugs: The demand for cheaper alternatives due to cost savings and the rise in over-the-counter drugs is expected to lure consumers towards generic APIs. This is further supported by drugs going off patent. Rising Adoption of Biopharmaceuticals: Biotech APIs are expected to grow rapidly due to the increased demand for biopharmaceuticals and innovations in the field to meet medical needs for various diseases. Increasing Healthcare Expenditure: The rising healthcare expenditure in France leads to a greater focus on developing effective and safe drugs, propelling the market growth. Government Initiatives and Support: The French government is being urged to take more initiative and appeal for policies to encourage manufacturers to produce drugs and APIs within the country.

The size of the France Active Pharmaceutical Ingredients (API) market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 6.10% during the forecast period. The active pharmaceutical ingredients, or APIs, are the active moieties of drugs that provide the desired therapeutic action. These are the molecules that treat or control disease. APIs can be of natural sources, such as plants and animals, or synthesized through complex chemical processes. Once the APIs are produced, they are mixed with other substances called excipients, which aid in the formulation and delivery of the medicine. The use of APIs extends far beyond many therapeutic areas like oncology, cardiology, neurology, to name a few. More importantly, they play critical roles in the development and manufacturing of pharmaceuticals about ensuring the availability of these basic medicines to patients from most parts of the world. Recent developments include: October 2022: MilliporeSigma opened a 700-square-meter (29,000-square-foot) commercial facility for its new Millipore CTDMO Services in France to produce monoclonal antibodies and other recombinant proteins. The CTDMO service spans pre-clinical to commercial phases, including testing, across multiple modalities, including mAbs, highly potent active pharmaceutical ingredients, antibody-drug conjugates, viral vector therapies, mRNA, and lipid nanoparticle formulation., July 2022: As part of a wider project funded by the 'France Relance' Plan, the Novasep-PharmaZell Group committed EUR 7.3 million in its Mourenx facility (southwestern France) to build a multipurpose pilot workshop inside one of its production units. The new industrial instrument will support the development of the Mourenx site and the ongoing need to produce active pharmaceutical ingredients (APIs), particularly the highly potent medicines (HPAPIs) used to treat cancer.. Key drivers for this market are: Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders, Increasing Adoption of Biologicals and Biosimilars; Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drugs Research. Potential restraints include: Stringent Regulations and Drug Price Control Policies. Notable trends are: Oncology Segment Expects to Register a Healthy CAGR.